ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ABUS vs IMMX // EV/EBITDA & P/E VALUATION

Arbutus Biopharma Corporation (NASDAQ) VS. Immix Biopharma Inc. (NASDAQ) • 15-METRIC TALLY: ABUS 2 — IMMX 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ABUS VS. IMMX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ABUS IMMX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -6.04% -3.73% -2.31 IMMX /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) 128.20% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 1.34 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 2/9 +1.00 ABUS /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 39.9 30.3 +9.61 ABUS /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $656.0M $661.6M -$5.5M IMMX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ABUS REV IMMX REV ABUS GROSS % IMMX GROSS % ABUS FCF IMMX FCF
FY 2025 $14.1M $0 — — -$39.6M -$24.7M
FY 2024 $6.2M $0 — — -$65.0M -$15.8M
FY 2023 $18.1M $0 — — -$85.9M -$11.4M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ABUS // BETA —
IMMX // BETA —